James B. Spicer

Dec 5, 2024 | nature.com | Sanjay Popat |James B. Spicer |Allan Hackshaw

AbstractHere we present long-term outcomes of first line afatinib in comorbid patients with suspected or confirmed EGFR mutant NSCLC otherwise considered unsuitable for chemotherapy, and the clinical utility of serial ctDNA monitoring. TIMELY (NCT01415011) was a multicentre, single arm, phase II trial conducted in the UK. Patients aged ≥18 were treated with daily oral afatinib (40 mg) until disease progression or unacceptable toxicity.

Jan 22, 2024 | thesentinel.com | James B. Spicer

Mary Emily Howes, 89, of Hagerstown, MD, passed away on Wednesday, January 17, 2024, at Somerford Place. Born October 26, 1934, in Glenwood, MD, she was the daughter of the late James Franklin Givens, Sr. and wife, Eva Hattie (Seal). Mary was a resident of Howard and Montgomery Counties before moving to Hagerstown in 1999. She was a 1952 graduate of Gaithersburg High School, receiving the Commercial Award.

Jul 25, 2023 | nature.com | James B. Spicer |Udai Banerji |Rebecca S Kristeleit |Rowan Miller |Christopher J Corrigan |Silvana Canevari | +8 more

AbstractAll antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing the relevant antigen, folate receptor-alpha.

Apr 25, 2023 | nature.com | Tony Cheung |Chara Stavraka |Giulia Pellizzari |Francis Man |Hannah Gould |Andrew J. Beavil | +4 more

AbstractOutcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective immunotherapies directed at CSPG4 could benefit many patients. Since IgE exerts potent immune-activating functions in tissues, we engineer a monoclonal IgE antibody with human constant domains recognizing CSPG4 to target melanoma.